TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The formulation further comprises: preferably other forms of prasugrel beside the prasugrel free base; at least one or more excipient(s), which comprise fillers, disintegrants, binders, lubricants, glidants, sweeteners, aromatic agents, preservatives, and/or coloring agents. Preferred Components: The percentage purity of prasugrel free base is at least 99% (preferably at least 99.5%). The other forms of prasugrel contained in the formulation beside the prasugrel free base are prasugrel isomers, enantiomers, racemates, salts (preferably hydrochloride and maleate salts), the solvates and/or hydrates of these salts. The amount of prasugrel free base is 1-90% (preferably 10-60%). The mean particle size of prasugrel free base contained in the formulation is 1-100 mm, preferably 5-20 mm. The fillers comprise mannitol, spray-dried mannitol, microcrystalline cellulose, pullulan and similar polysaccharides, dibasic calcium phosphate dihydrate, lactose, sugars, sorbitol, mixture of microcrystalline cellulose and guar gum, mixture of mannitol, Polyplasdone(RTM: Crosslinked polyvinlypyrrolidone) and Syloid( RTM: Silicon dioxide), mixture of mannitol, crospovidone and polyvinyl acetate, isomalt, Panexcea (RTM: Multifunctional performance excipients), F-Melt (RTM: Proprietary spray-dried powder), sucrose, calcium salts and similar inorganic salts, and/or heavy magnesium carbonate. The amount of the fillers is 1-90% (preferably 10-75%). The disintegrants comprise at least one or a mixture of sodium starch glycolate, croscarmellose sodium, crospovidone, sodium alginate, gums, starch, and magnesium aluminum silicate. The weight ratio of the filler to the disintegrant is 80:1-1:20 (preferably 30:1-1:5). The binders comprise polyvinylpyrrolidone (povidone), gelatin, sugars, glucose, natural gums, gums, synthetic celluloses, polymethacrylate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, methyl cellulose and/or other cellulose derivatives. The lubricants comprise sodium stearyl fumarate, magnesium stearate, polyethylene glycol, stearic acid, metal stearates, boric acid, sodium chloride benzoate and acetate, hydrogenated castor oil, sodium and/or magnesium lauryl sulfate. The glidants comprise colloidal silicon dioxide, talk, and/or aluminum silicate. The sweeteners comprise aspartam, sucralose, saccharine; glucose, lactose, fructose and other sugars, and mannitol, sorbitol, xylitol, and/or erythritol. The aromatic agents comprise menthol, mint, cinnamon, chocolate, vanillin, and fruit extracts such as cherry, orange, strawberry, and/or grape. Preferred Method: The method comprises mixing the filler and the disintegrant among the excipients except for the active agent in a container to form mixture A, and mixing the other excipients in a separate container to form mixture B. ACTIVITY - Anticoagulant; Thrombolytic; Cardiovascular-Gen.    MECHANISM OF ACTION - Purinergic receptor (P2Y) G-protein coupled 12 inhibitor; Adenosine diphosphate receptor inhibitor.    ADMINISTRATION - Administration of the formulation is oral, parenteral, ocular, nasal, buccal, sublingual, transdermal, transmucosal, intramuscular, rectal, topical, or by inhalation, in the form of solid, tablet, dragee, capsule, caplet, orally-disintegrating tablet, film-coated tablet, enteric tablet, buccal tablet, sublingual tablet, chewable tablet, effervescent tablet, slow-release tablet, rapid-release tablet, modified-release tablet, delayed-release tablet, prolonged-release, controlled-release tablet, sachet, granule, pilule, powder, pellet, suppository, or pastille (claimed). Administration of the formulation is 5 mg or 10 mg.    EXAMPLE - Typical formulation comprised of: 25-45% of prasugrel free base; 30-50% of lactose; 1-10% of microcrystalline cellulose; 1-15% of polyethylene glycol; 1-20% of hydroxypropyl cellulose; and 1-5% of hydrogenated castor oil.